Explainer
HIV explained: testing, treatment, PrEP and lenacapavir
HIV is a virus that attacks the immune system, and AIDS is the most advanced stage of infection.[1] There is no cure, but antiretroviral therapy stops the virus replicating, and people on treatment with an undetectable viral load do not pass HIV to sexual partners.[2][3] An estimated 41.0 million people were living with HIV at the end of 2025, and 1.2 million acquired it that year.[4][5] WHO now recommends four PrEP options, including twice-yearly injectable lenacapavir, which the US FDA approved for prevention in June 2025.[6][7][8]
This page explains HIV for general readers. It is not medical advice. If you think you may have been exposed to HIV, or you want to know whether PrEP or treatment is right for you, talk to a clinician or a sexual health service.
The world-health-organization describes HIV (human immunodeficiency virus) as a virus that attacks the body’s immune system; AIDS is the most advanced stage of infection.[1] There is still no cure, but antiretroviral drugs stop the virus replicating, and WHO has added twice-yearly injectable lenacapavir to the prevention options.[2][8]
How HIV spreads, and how it doesn’t
HIV is passed on through body fluids of a person with HIV, including blood, breast milk, semen and vaginal fluids, and it can pass from mother to baby. It is not spread by kissing, hugging or sharing food.[9]
Treatment also prevents transmission. WHO says people living with HIV who take antiretroviral therapy (ART) and have an undetectable viral load will not transmit HIV to their sexual partners.[3]
In the first few weeks after infection, some people have no symptoms, while others have a flu-like illness with fever, headache, rash or sore throat.[10]
Testing and the 28-day window
HIV can be diagnosed with rapid tests that give same-day results, and people can also use self-tests. No single test gives a full diagnosis, though: a positive result has to be confirmed by a trained health or community worker.[11]
Most people develop antibodies to HIV within 28 days of infection. WHO says people who test negative after a recent high-risk exposure can take another test after 28 days.[12]
Treatment
HIV is treated with antiretroviral drugs, which stop the virus from replicating in the body.[2] UNAIDS says 32.1 million people were on antiretroviral therapy at the end of 2025, up from 7.6 million in 2010.[13]
Injectable treatment is now an option for some people. WHO’s July 2025 guidelines added long-acting injectable cabotegravir plus rilpivirine as an alternative for adults and adolescents who are already virally suppressed on oral ART.[14]
PrEP, PEP and lenacapavir
Antiretroviral drugs can also prevent infection in people who do not have HIV. Taken before a possible exposure, this is called pre-exposure prophylaxis (PrEP); taken after an exposure, it is post-exposure prophylaxis (PEP). WHO advises people to seek a clinician’s advice when considering either.[15]
WHO recommends four PrEP methods: oral tenofovir-based PrEP, the dapivirine vaginal ring, long-acting injectable cabotegravir and long-acting injectable lenacapavir.[6]
Lenacapavir is the newest. The US Food and Drug Administration approved it for HIV prevention in June 2025, following 2024 results from the PURPOSE 1 and PURPOSE 2 clinical trials.[7] On 14 July 2025 WHO issued guidelines recommending lenacapavir, injected twice a year, as an additional PrEP option.[8] At that point WHO said access outside clinical trials remained limited.[16] For how US approvals work, see how FDA drug approval works.
The global picture
An estimated 41.0 million people were living with HIV at the end of 2025, 64% of them in the WHO African Region.[4] In 2025 about 1.2 million people acquired HIV and 570,000 died from HIV-related causes.[5]
The long-term trend is downward. UNAIDS says new infections have fallen 65% since their 1994 peak, and AIDS-related deaths have fallen 73% since their 2004 peak.[17]
In 2025, 88% of people with HIV knew their status, 89% of those were on treatment, and 95% of people on treatment had a suppressed viral load, close to the global “95-95-95” targets.[18] WHO, the Global Fund and UNAIDS all have strategies aligned with the UN Sustainable Development Goal of ending the HIV epidemic by 2030.[19]
People living with HIV are 12 times more likely to fall ill with tuberculosis, and TB is the leading cause of death among people with HIV; see tuberculosis explainer.[20] Related infections are covered in hepatitis B and C explainer and mpox explainer.
Read next
World Health Organization (WHO)
The UN agency for health: how WHO is governed and funded, the US withdrawal that took effect in January 2026, and the Pandemic Agreement's unfinished annex.
Questions readers ask
How is HIV spread?
Through body fluids of a person with HIV, including blood, breast milk, semen and vaginal fluids, and from mother to baby. WHO says it is not spread by kissing, hugging or sharing food.[9]
How soon after exposure can an HIV test detect infection?
Most people develop antibodies to HIV within 28 days. WHO says someone who tests negative after a recent high-risk exposure can test again after 28 days, and any positive result needs confirmatory testing.[12][11]
Can people on HIV treatment pass the virus on?
WHO says people living with HIV who take antiretroviral therapy and have an undetectable viral load will not transmit HIV to their sexual partners.[3]
What is PrEP?
Pre-exposure prophylaxis is antiretroviral medicine taken by HIV-negative people before possible exposure. WHO recommends oral tenofovir-based PrEP, the dapivirine ring, injectable cabotegravir and injectable lenacapavir, and advises talking to a clinician first.[6][15]
What is lenacapavir?
A long-acting injectable antiretroviral given twice a year as PrEP. The US FDA approved it for HIV prevention in June 2025 after the PURPOSE 1 and 2 trials, and WHO recommended it in July 2025.[7][8]
Is there a cure for HIV?
No. HIV is treated with antiretroviral drugs that stop the virus replicating in the body.[2]
Sources
· 20 claims from 2 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
WHO describes HIV as a virus that attacks the immune system; AIDS is the most advanced stage of infection. confirmedas of 2026-11-07
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Overview (retrieved 2026-11-07)
- [2]
There is no cure for HIV; it is treated with antiretroviral drugs that stop the virus replicating. confirmedas of 2026-11-07
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Treatment (retrieved 2026-11-07)
- [3]
WHO says people with HIV who take antiretroviral therapy and have an undetectable viral load will not transmit HIV to sexual partners. confirmedas of 2026-11-07
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Transmission (retrieved 2026-11-07)
- [4]
An estimated 41.0 million people were living with HIV at the end of 2025, 64% of them in the WHO African Region. confirmedas of 2026-11-07
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Key facts (retrieved 2026-11-07)
- Global HIV & AIDS statistics - Fact sheet · UNAIDS · Primary source · Global HIV statistics: 41.0 million (retrieved 2026-11-07)
- [5]
In 2025 an estimated 1.2 million people acquired HIV and 570,000 died from HIV-related causes. confirmedas of 2026-11-07
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Key facts (retrieved 2026-11-07)
- [6]
WHO recommends four PrEP methods: oral tenofovir-based PrEP, the dapivirine vaginal ring, injectable cabotegravir and injectable lenacapavir. confirmedas of 2026-11-07
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Prevention (retrieved 2026-11-07)
- [7]
The US FDA approved injectable lenacapavir for HIV prevention in June 2025, following the 2024 PURPOSE 1 and PURPOSE 2 trials. confirmedas of 2026-11-07
- FDA approval of injectable lenacapavir marks progress for HIV prevention · World Health Organization · Primary source · 2025-06-19 · Published 19 June 2025 (retrieved 2026-11-07)
- FDA approval of injectable lenacapavir marks progress for HIV prevention · World Health Organization · Primary source · 2025-06-19 (retrieved 2026-11-07)
- [8]
On 14 July 2025 WHO issued guidelines recommending twice-yearly injectable lenacapavir as an additional PrEP option. confirmedas of 2026-11-07
- WHO recommends injectable lenacapavir for HIV prevention · World Health Organization · Primary source · 2025-07-14 · 14 July 2025 (retrieved 2026-11-07)
- [9]
HIV spreads through body fluids including blood, breast milk, semen and vaginal fluids, and can pass from mother to baby; it does not spread through kissing, hugging or sharing food. confirmedas of 2026-11-07
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Overview (retrieved 2026-11-07)
- [10]
In the first weeks after infection some people have no symptoms, while others have a flu-like illness with fever, headache, rash or sore throat. confirmedas of 2026-11-07
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Signs and symptoms (retrieved 2026-11-07)
- [11]
HIV can be diagnosed with same-day rapid tests and self-tests, but a positive result needs confirmatory testing by a trained health or community worker. confirmedas of 2026-11-07
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Diagnosis (retrieved 2026-11-07)
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Diagnosis (retrieved 2026-11-07)
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Diagnosis (retrieved 2026-11-07)
- [12]
Most people develop detectable HIV antibodies within 28 days of infection; WHO says people who test negative after a recent high-risk exposure can test again after 28 days. confirmedas of 2026-11-07
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Diagnosis (retrieved 2026-11-07)
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Diagnosis (retrieved 2026-11-07)
- [13]
UNAIDS says 32.1 million people were on antiretroviral therapy at the end of 2025, up from 7.6 million in 2010. confirmedas of 2026-11-07
- Global HIV & AIDS statistics - Fact sheet · UNAIDS · Primary source · People living with HIV accessing antiretroviral therapy: 32.1 million at end of December 2025 (retrieved 2026-11-07)
- [14]
WHO's July 2025 treatment guidelines added injectable cabotegravir plus rilpivirine as an alternative for adults and adolescents already virally suppressed on oral ART. confirmedas of 2026-11-07
- WHO recommends injectable lenacapavir for HIV prevention · World Health Organization · Primary source · 2025-07-14 · Additional WHO recommendations (retrieved 2026-11-07)
- [15]
Antiretroviral drugs taken before possible exposure are called PrEP and after exposure PEP; WHO advises people to seek a clinician's advice when considering either. confirmedas of 2026-11-07
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Prevention (retrieved 2026-11-07)
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Prevention (retrieved 2026-11-07)
- [16]
When WHO issued its lenacapavir guidelines in July 2025, it said access outside clinical trials remained limited. confirmedas of 2026-11-07
- WHO recommends injectable lenacapavir for HIV prevention · World Health Organization · Primary source · 2025-07-14 · Next steps (retrieved 2026-11-07)
- [17]
UNAIDS says new HIV infections have fallen 65% since their 1994 peak and AIDS-related deaths 73% since their 2004 peak. confirmedas of 2026-11-07
- Global HIV & AIDS statistics - Fact sheet · UNAIDS · Primary source · New HIV infections (retrieved 2026-11-07)
- Global HIV & AIDS statistics - Fact sheet · UNAIDS · Primary source · AIDS-related deaths (retrieved 2026-11-07)
- [18]
In 2025, 88% of people with HIV knew their status, 89% of those were on treatment and 95% of those on treatment had suppressed viral loads, close to the 95-95-95 targets. confirmedas of 2026-11-07
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Key facts (retrieved 2026-11-07)
- [19]
WHO, the Global Fund and UNAIDS have HIV strategies aligned with the SDG target of ending the HIV epidemic by 2030. confirmedas of 2026-11-07
- HIV and AIDS - fact sheet · World Health Organization · Primary source · Key facts (retrieved 2026-11-07)
- [20]
People living with HIV are 12 times more likely to fall ill with TB, and TB is the leading cause of death among people with HIV. confirmedas of 2026-11-07
- Tuberculosis - fact sheet · World Health Organization · Primary source · TB and HIV (retrieved 2026-11-07)
Revision history (1)
- Page created.
Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Feb 15, 2027.
Cite this page
"HIV explained: testing, treatment, PrEP and lenacapavir." ContentLora, updated Nov 7, 2026. https://contentlora.com/explain/hiv-explained
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.